Skip to Content
Morningstar
Get 14 Days Free

McKesson Corp MCK

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Reaffirming Our Narrow Moat and Negative Moat Trend on the Big Three U.S. Pharma Wholesalers

Dylan Finley, CFA Equity Analyst

Analyst Note

| Dylan Finley, CFA |

After taking a refreshed look at the U.S. pharmaceutical wholesale industry, we are reaffirming our narrow moat and negative moat trend ratings, and we have revised our fair value estimates--with AmerisourceBergen at $142 per share (previously $135), McKesson at $210 per share (previously $198), and Cardinal Health at $55 per share (previously $60). These revisions reflect slightly higher revenue growth assumptions overall, a reworking of our gross and operating margin estimates, our updated long-term U.S. tax rate estimate of 26%, and the financial impact associated with a looming multi-billion dollar opioid settlement.

Read Full Analysis

Company Profile

Business Description

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. Outside the U.S. market, McKesson engages in pharmaceutical wholesale and distribution in Europe and Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Contact
6555 State Highway 161
Irving, TX, 75039
T +1 972 446-4800
Sector Healthcare
Industry Medical Distribution
Most Recent Earnings Jun 30, 2021
Fiscal Year End Mar 31, 2022
Stock Type Classic Growth
Employees 76,000

Related

Sustainability Matters
What Investors Should Know About the $26 Billion Opioid Settlement
We review potential impact on valuation for the four companies involved.
Karen Wallace
Stock Strategist Industry Reports
COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic
Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.
Karen Andersen
Stock Strategist Industry Reports
A Coronavirus Vaccine, or Three, Could Be Available by Year-End
We expect multiple approved vaccines by early 2021 with wide vaccine distribution in developed markets by mid-2021.
Karen Andersen
Fund Spy
Few Can Match Vanguard Dividend Growth's Reliability
The Gold-rated fund continues to prove its worth during volatile markets.
Alec Lucas
Our Picks
15 Top-Quality Stocks
These names were recently added to the Morningstar Wide Moat Focus Index.
Susan Dziubinski
Stock Strategist Industry Reports
What Opioid Litigation Means for Healthcare Stocks
It continues to inflict pain on drug manufacturers and distributors.
Soo Romanoff
Our Picks
10 Cheap Wide-Moat Stocks
We review the changes to the Morningstar Wide Moat Focus Index during the latest reconstitution and reveal the least-expensive names.
Susan Dziubinski
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended April 12.
Morningstar.com
Stock Strategist Industry Reports
Lowering Our Pharma Distributor Moat Ratings and Valuations
All three companies still trade at 4 stars, however.
Soo Romanoff
Our Picks
30 Undervalued Stocks
Here are some of our analysts' best ideas across sectors.
Susan Dziubinski
Quarter-End Insights
Healthcare: Stock-Picking Increasingly Important
Drug manufacturers and healthcare providers offer the most upside.
Damien Conover
Stock Analyst Update
Steady Top-Line Growth for McKesson
The wide-moat firm's core drug distribution business posted gains of 6% in results that were largely in line with expectations.
Damien Conover
Premium Article
25 Cheap Stocks
These low- and medium-uncertainty stocks are trading at the largest discounts to our fair value estimates.
Susan Dziubinski
Quarter-End Insights
Healthcare: Specter of ACA Repeal Hangs Over Fairly Valued Sector
We expect appeals to delay any impact but revoking the ACA would likely create the most pressure for the healthcare services companies.
Damien Conover
Premium Article
Are These Wide-Moat Stocks Subpar?
More than 50 stocks derive their wide moats from just one source. Is that a problem?
Susan Dziubinski
Stock Strategist
Cardinal's a Critical Link in the Pharma Supply Chain
Its core operations will be needed no matter how market dynamics shift.
Vishnu Lekraj
Premium Article
4 Doorbusters for Investors
These high-quality stocks are cheap on a host of metrics.
Susan Dziubinski
Investing Specialists
More Tax Pain for Some Mutual Fund Shareholders in 2018
Ongoing redemptions from active funds and a long-running bull market mean tax pain for many fund investors in taxable accounts.
Christine Benz
Investing Specialists
Tax-Loss Selling: A Silver Lining in Volatile Markets
Pruning losers can reduce the tax hit from rebalancing and mutual fund capital gains distributions.
Christine Benz
Stock Strategist
McKesson Is Deeply Discounted
The pharma distributor has a solid foundation and a bright outlook, in our opinion.
Vishnu Lekraj

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.